Satraplatin for HRPC Phase III Trial Filled
GPC Biotech completes enrolment in phase III trial for cancer drug Satraplatin
AFX News Limited/Forbes.com, 12.05.2005
MARTINSRIED, Germany (AFX) - GPC Biotech AG said it has completed the targeted enrolment of patients for its Phase III trial of the Satraplatin drug to treat hormone-refractory prostate cancer (HRPC).
The Germany biotech company said more than 200 clinical sites in fifteen countries have now accrued a total of 912 patients for the trial.
The trial, named SPARC (Satraplatin and Prednisone Against Refractory Cancer), is a double blind, randomised study that is assessing the safety and efficacy of Satraplatin in combination with prednisone as a second-line chemotherapy in patients with hormone-refractory prostate cancer (HRPC).
(full story…)